Centinel Spine reports record fourth quarter revenue

NewsGuard 100/100 Score

Centinel Spine, Inc. (Centinel), a market leader in the development, manufacture and distribution of Integrated Interbody Fusion™ devices, today announced a record 41.8% revenue increase during the 4th quarter, 2010, vs. 3rd quarter, 2010. Also, during the 4th quarter, 2010, Centinel achieved a record setting 32.5% gain vs. the same period in 2009.

“There are many new and varied options available for patients and their surgeons in the treatment of spinal disc problems, however, surgeons are finding Centinel's ground-breaking implant designs are as relevant or more-so today than when they were first introduced.”

Announcing the results, Centinel's Chairman and CEO, John J. Viscogliosi, said, "We are extremely pleased, but certainly not surprised, by Q4's huge revenue increase and record results. A confluence of positive events continued for us in the 4th quarter as we initiated our new STALIF MIDLINE™ alpha launch, while support from surgeons using our STALIF C™ and STALIF TT™ Integrated Interbody fusion devices continued on an exponential growth path. Looking forward, we fully expect the first quarter of this year and the balance of 2011 to continue with similar stellar results."

Commenting on the results, Centinel's President, Michael D. Will, said, "There are many new and varied options available for patients and their surgeons in the treatment of spinal disc problems, however, surgeons are finding Centinel's ground-breaking implant designs are as relevant or more-so today than when they were first introduced."

Mr. Will added: "With the continued evolution of our STALIF line of products, more and more surgeons are recommending Centinel's solutions and great products are what ultimately drive growth."

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The effects of high maternal folate intake on the health outcomes of offspring